The DNMBP Knockout K-562 Polyclonal Cells product consists of a polyclonal population of human K-562 chronic myelogenous leukemia cells that have been subjected to CRISPR/Cas9-mediated gene disruption targeting the DNMBP locus. This polyclonal knockout cell pool provides a loss-of-function model for investigating the roles of DNMBP in hematopoietic cell biology, particularly in the context of leukemia-associated signaling networks. The polyclonal format avoids clonal biases and represents a heterogeneous edited population, suitable for comparative studies alongside wild-type K-562 controls. Researchers can employ this model to dissect DNMBP-dependent molecular mechanisms without the confounding effects of monoclonal artifacts, enabling robust functional genomics and drug response analyses in a hematological malignancy background.
K-562 cells are a widely used human cell line derived from a 53-year-old female patient with chronic myelogenous leukemia in blast crisis. These multipotent hematopoietic cells harbor the Philadelphia chromosome, which generates the BCR-ABL1 fusion oncogene, and serve as a classic model for CML pathobiology and erythroid differentiation studies. K-562 cells exhibit suspension growth characteristics and express markers of erythroid, granulocytic, and monocytic lineages, making them versatile for investigating signaling pathways that govern proliferation, differentiation, and apoptosis in leukemia. Their genetic tractability and extensive characterization render them an ideal host for CRISPR-mediated gene editing and subsequent functional assays.
DNMBP (also known as Tuba) encodes a multi-domain scaffold protein that directly links dynamin-mediated membrane trafficking to the actin cytoskeleton. It functions as a guanine nucleotide exchange factor specific for CDC42, a Rho family GTPase, and is activated downstream of receptor tyrosine kinases and integrin signaling. Through its N-terminal BAR domain, DNMBP interacts with dynamin 1 and 2 to facilitate clathrin-mediated endocytosis and vesicle scission, while its C-terminal SH3 domains bind cortactin and actin, coordinating actin polymerization at endocytic sites and cell-cell junctions. DNMBP-mediated CDC42 activation triggers PAK1 kinase signaling, which in turn phosphorylates downstream effectors such as WASP and the ARP2/3 complex, driving localized actin remodeling. At tight junctions, DNMBP recruits ZO-1 and occludin, thereby regulating epithelial barrier integrity and cell polarity.
In the K-562 leukemia model, DNMBP disruption enables the study of CDC42-driven actin dynamics and migration independently of epithelial constraints. Although K-562 cells are of hematopoietic origin and do not form classical tight junctions, they express junction-associated proteins that may contribute to cell-cell adhesion and leukemic niche interactions. Knockout of DNMBP may perturb CDC42 activation and PAK signaling, altering cell migration, invasion, and chemotaxis, which are critical processes in leukemic dissemination and drug resistance. This model provides a unique opportunity to explore how a traditionally epithelial junctional regulator impacts hematopoietic cell functions, potentially uncovering novel vulnerabilities in BCR-ABL1-positive leukemia cells.
This polyclonal knockout cell pool is well-suited for a variety of functional assays, including transwell migration assays, gelatin zymography to assess matrix metalloproteinase activity, and flow cytometry for surface marker profiling. Researchers can perform co-immunoprecipitation and GST-PAK pull-down assays to validate DNMBP interactions and CDC42 activation, while western blotting and RT-qPCR enable quantification of downstream targets such as ZO-1 and occludin. Drug sensitivity screening and apoptosis assays (e.g., Annexin V/PI staining) facilitate the evaluation of therapeutic responses in a DNMBP-deficient background. RNA-seq analysis may reveal transcriptomic alterations linked to cell adhesion and motility pathways. For further details, please contact Ascent Research.
